人福医药：氢可酮布洛芬片获药品注册证书

Core Viewpoint - The company Yichang Renfu Pharmaceutical Co., a subsidiary of Renfu Pharmaceutical (600079), has received approval from the National Medical Products Administration for the registration of Hydrocodone Ibuprofen Tablets, marking it as the first product of its kind approved for domestic market use [1] Group 1: Product Approval - The Hydrocodone Ibuprofen Tablets are indicated for the relief of acute pain and should be used when alternative treatments (such as non-opioid medications) are intolerable or insufficient [1] - The product has not yet been launched in the domestic market, making it a pioneering approval in China [1] Group 2: Development Timeline and Investment - Yichang Renfu submitted the application for the marketing authorization of Hydrocodone Ibuprofen Tablets to the National Medical Products Administration in November 2022, which was accepted [1] - The total research and development investment for this project has reached approximately 20 million RMB [1]